Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

With healthcare costs dominating the conversation in recent years, the topic of employer-covered healthcare is a key issue.

Jun Gong, MD, associate professor of medicine and medical director of colorectal cancer at Cedars-Sinai, spoke with ...

FDA cleared belzutifan 120 mg plus lenvatinib 20 mg daily for advanced RCC with a clear cell component after prior PD-1/PD-L1 inhibitor exposure. LITESPARK-011 randomized 747 patients to ...

Novo Nordisk secured Pharmashell access for up to five peptide programs, targeting long-acting injectable profiles and offering Nanexa >$1.33B total consideration plus low single-digit royalties.

FDA authorization is underpinned by four global Phase III QWINT studies showing non-inferior A1C lowering versus glargine ...

The agreement provides up to $100 million upfront/near-term and up to ~$3.25 billion in milestones, plus single-digit tiered royalties, reflecting high optionality typical of early discovery ...

EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business ...

Chief executives from nine of Europe's largest drugmakers are calling on the European Union (EU) and its member states to ...

InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin ...

The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong.

Novo is open to considering a direct listing of its shares on the New York Stock Exchange, chief executive officer Mike Doustdar told the Financial Times. The shift to listing shares directly would ...